1 – 23 of 23
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept : Results from the international TOCERRA and PANABA observational collaborative studies
(
- Contribution to journal › Article
- 2022
-
Mark
Characterization and outcomes of 414 patients with primary SS who developed hematological malignancies
(
- Contribution to journal › Article
- 2021
-
Mark
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome
(
- Contribution to journal › Article
- 2020
-
Mark
Autoimmune congenital heart block and primary Sjögren's syndrome : characterisation and outcomes of 49 cases
(
- Contribution to journal › Article
-
Mark
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
(
- Contribution to journal › Article
- 2019
-
Mark
Efficacy and safety of topical and systemic medications : A systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)
(
- Contribution to journal › Article
-
Mark
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients : A cross-sectional study from the Big Data Sjögren Project Consortium
(
- Contribution to journal › Article
- 2016
-
Mark
Sjögren syndrome
(
- Contribution to journal › Article
-
Mark
Development of the ClinESSDAI : A clinical score without biological domain. A tool for biological studies
(
- Contribution to journal › Article
-
Mark
Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations.
(
- Contribution to journal › Scientific review
-
Mark
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
(
- Contribution to journal › Article
-
Mark
Off-label use of rituximab for systemic lupus erythematosus in Europe
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.
(
- Contribution to journal › Article
-
Mark
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Outcome measures for primary Sjögren's syndrome: A comprehensive review.
(
- Contribution to journal › Scientific review
-
Mark
Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
(
- Contribution to journal › Article
- 2013
-
Mark
Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue
(
- Contribution to journal › Article
-
Mark
NCR3/NKp30 Contributes to Pathogenesis in Primary Sjogren's Syndrome
(
- Contribution to journal › Article
- 2012
-
Mark
Outcome measures for primary Sjogren's syndrome
(
- Contribution to journal › Scientific review
- 2011
-
Mark
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome
(
- Contribution to journal › Article
- 2010
-
Mark
Accurate Detection of Changes in Disease Activity in Primary Sjogren's Syndrome by the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index
(
- Contribution to journal › Article
-
Mark
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome
(
- Contribution to journal › Article